For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Nuvation Bio Inc (NYSE: NUVB) closed at $3.41 down -6.06% from its previous closing price of $3.63. In other words, the price has decreased by -$6.06 from its previous closing price. On the day, 5.83 million shares were traded. NUVB stock price reached its highest trading level at $3.615 during the session, while it also had its lowest trading level at $3.36.
Ratios:
For a deeper understanding of Nuvation Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.38 and its Current Ratio is at 9.39. In the meantime, Its Debt-to-Equity ratio is 0.55 whereas as Long-Term Debt/Eq ratio is at 0.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on September 30, 2025, initiated with a Buy rating and assigned the stock a target price of $10.
On April 23, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $6.
Jefferies Upgraded its Hold to Buy on March 27, 2024, whereas the target price for the stock was revised from $1.40 to $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 18 ’25 when Markel Stacy bought 10,000 shares for $1.71 per share. The transaction valued at 17,100 led to the insider holds 29,591 shares of the business.
Sauvage Philippe bought 4,000 shares of NUVB for $7,160 on Jun 17 ’25. The Chief Financial Officer now owns 9,902 shares after completing the transaction at $1.79 per share. On Jun 16 ’25, another insider, Sauvage Philippe, who serves as the Chief Financial Officer of the company, bought 3,300 shares for $1.83 each. As a result, the insider paid 6,056 and bolstered with 5,902 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 1167150080 and an Enterprise Value of 617192000. For the stock, the TTM Price-to-Sale (P/S) ratio is 81.52 while its Price-to-Book (P/B) ratio in mrq is 3.09. Its current Enterprise Value per Revenue stands at 42.995 whereas that against EBITDA is 3.063.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.47, which has changed by 0.4449153 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $4.09, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 6.28%, while the 200-Day Moving Average is calculated to be 39.02%.
Shares Statistics:
For the past three months, NUVB has traded an average of 6.00M shares per day and 6353110 over the past ten days. A total of 336.84M shares are outstanding, with a floating share count of 231.51M. Insiders hold about 32.56% of the company’s shares, while institutions hold 53.54% stake in the company. Shares short for NUVB as of 1759190400 were 71969817 with a Short Ratio of 12.00, compared to 1756425600 on 68130174. Therefore, it implies a Short% of Shares Outstanding of 71969817 and a Short% of Float of 34.300000000000004.
Earnings Estimates
As of right now, 1.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.55 and -$0.55 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.52, with 1.0 analysts recommending between -$0.52 and -$0.52.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $6.86M this quarter.It ranges from a high estimate of $10.3M to a low estimate of $4.43M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $727kFor the next quarter, 5 analysts are estimating revenue of $16.24M. There is a high estimate of $31.5M for the next quarter, whereas the lowest estimate is $8.76M.
A total of 7 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $52.9M, while the lowest revenue estimate was $21.1M, resulting in an average revenue estimate of $32.98M. In the same quarter a year ago, actual revenue was $7.87MBased on 7 analysts’ estimates, the company’s revenue will be $137.58M in the next fiscal year. The high estimate is $209.59M and the low estimate is $79.1M.
